Analysts and consensus

Analyst Coverage

Bank	Analyst	Location
SEB	Christopher Uhde	Stockholm
ABG Sundal Collier	Alexander Krämer	Stockholm
Van Lanschot Kempen	Suzanne van Voorthuizen	Amsterdam
Carnegie	Erik Hultgård	Stockholm
H.C. Wainwright & Co.	Douglas Tsao	New York City
William Blair	Matt Phipps	Chicago
Leerink Partners LLC	Thomas J. Smith	New York City / Boston
Jefferies LLC	Farzin Haque, Ph.D.	New York City

* - Both Jefferies and Leerink Partners initiated coverage of Hansa Biopharma AB in Q4 2025

Analyst Consensus

Company collected consensus updated on a quarterly basis after the publication of the latest financial report. Latest updated April 23, 2025.

			Revenue estimates, SEKm
Consensus model	Price target, SEK	WACC	FY'25e	FY'26e	FY'27e
Average	95	17%	266	563	1 307
Median	97	17%	257	574	1 328
High	143	18%	301	698	1 935
Low	42	15%	240	406	638
Number of contributions	4	2	3	4	4

^{This is a company-collected consensus prepared with consolidated estimates submitted from research analysts covering the Hansa Biopharma stock. The consensus provided is based on a collection of estimates done on a quarterly basis.}^{Any opinions, forecasts, estimates, projections or predictions regarding Hansa Biopharma’s performance made by the analysts (and, therefore, the consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of Hansa Biopharma or its management.}^{Hansa Biopharma does not by providing these estimates imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations made or provided by such analysts. Hansa Biopharma assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.}